Journal
FEBS LETTERS
Volume 586, Issue 18, Pages 2897-2905Publisher
WILEY
DOI: 10.1016/j.febslet.2012.07.032
Keywords
Immunoregulatory molecules; Tolerance; Treg; Inflammation; Autoimmune diseases
Funding
- Spanish Ministry of the Economy
- Pro-CNIC Foundation
- [SAF2011-25834]
- [ERC-2011-AdG294340-GENTRIS]
Ask authors/readers for more resources
The balance between pro- and anti-inflammatory signalling is critical to maintain the immune homeostasis under physiological conditions as well as for the control of inflammation in different pathological settings. Recent progress in the signalling pathways that control this balance has led to the development of novel therapeutic agents for diseases characterized by alterations in the activation/suppression of the immune response. Different molecules have a key role in the regulation of the immune system, including the receptors PD-1 (Programmed cell Death 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) and galectins; or the intracellular enzyme IDO (indoleamine 2,3-dioxygenase). In addition, other molecules as CD69, AhR (Aryl hydrocarbon Receptor), and GADD45 (Growth Arrest and DNA Damage-inducible 45) family members, have emerged as potential targets for the regulation of the activation/suppression balance of immune cells. This review offers a perspective on well-characterized as well as emergent negative immune regulatory molecules in the context of autoimmune inflammatory diseases. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available